Quantcast

Latest Prostate cancer Stories

2014-05-30 12:25:59

WASHINGTON, May 30, 2014 /PRNewswire-USNewswire/ -- LUGPA will celebrate June as the start of Men's Health Month, urging men to take control of their health by educating themselves on important health issues. "Studies show that men are more likely to avoid going to the doctor than women, leaving them at the mercy of an unimaginable number of diseases and conditions that could have been prevented or improved if only they had talked to their doctor," said Dr. Juan Reyna, president of...

2014-05-30 08:25:19

Validation Data on More Than 300 Patients to be Released at the 2014 American Society of Oncology (ASCO) Annual Meeting REDWOOD CITY, Calif., May 30, 2014 /PRNewswire/ -- Guardant Health, a healthcare company focused on the development and commercialization of oncology diagnostic products, announced today that its premier product, Guardant360(TM) is now widely commercially available following recent successful introduction to early access partners....

2014-05-29 12:29:19

PRINCETON, N.J., May 29, 2014 /PRNewswire/ -- inVentiv Health Clinical, a leading global clinical research organization (CRO), and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing cancer immunotherapies, announced today that they have entered into a global master services agreement for the clinical development of certain immunotherapy product candidates in Advaxis's proprietary pipeline. inVentiv initially will work with Advaxis to develop clinical study protocols and will...

2014-05-29 08:30:55

Company Reported Positive Preliminary Responses in Phase I/II Trial Patients; Feuerstein Falsely Claims There Is No Positive Trial Information BETHESDA, Md., May 29, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, refuted the latest blatantly false and misleading statements made by Adam Feuerstein, in an article on Tuesday, May 27....

2014-05-29 08:29:44

SEATTLE, WA and HAMPTON, NJ, May 29, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) and Celldex Therapeutics, Inc., (NASDAQ: CLDX) today announced that they have agreed to collaborate on a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1. Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. The planned trial is an...

2014-05-29 08:29:37

New Data Presented at ASCO® Annual Meeting Suggest that Genomic Health's Oncotype DX Test May Help Identify Patients That Have the Greatest Opportunity to Benefit from Extended Hormonal Therapy REDWOOD CITY, Calif., May 29, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of a large, positive study that confirmed that the Oncotype DX® test results for Recurrence Score® and quantitative estrogen-receptor (ER) predict late distant recurrence risk in...

2014-05-29 08:27:06

2014 Public Service Announcement Once Again Rallies the Public to Help Raise Funds for Prostate Cancer Research LOS ANGELES and NEW YORK, May 29, 2014 /PRNewswire-USNewswire/ -- The Safeway Foundation and Stand Up To Cancer (SU2C), a program of the Entertainment Industry Foundation (EIF), have collaborated again to re-launch their public service campaign featuring actress and SU2C Celebrity Ambassador Marcia Cross, which will debut in June....

2014-05-29 04:21:52

ROCKLAND, Massachusetts, May 29, 2014 /PRNewswire/ -- ASCO abstract #: Anti-PD-L1: 3064; c-Met: 2521, TPS4151, TPS8121; tecemotide: TPS3658, TPS7608; TH-302: 8534, 2029; further pipeline: 3551, TPS9107, 5030, 2050, e13552 - Robust pipeline reflects commitment to innovation in oncology and immuno-oncology - Data from nine EMD Serono pipeline products across oncology and immuno-oncology to be presented, including anti-PD-L1, c-Met...

2014-05-28 20:22:42

Natesto(TM) is the first nasal testosterone replacement therapy approved by FDA TORONTO, May 28, 2014 /CNW/ - Trimel Pharmaceuticals Corporation (TSX: TRL) announced today that the United States Food and Drug Administration (FDA) has approved Natesto(TM) (testosterone), formerly CompleoTRT(TM), the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Natesto(TM) is...

2014-05-28 16:26:55

Educational and Awareness Raising Events Scheduled throughout the Month of June NEW YORK, May 28, 2014 /PRNewswire/ -- The Cancer Research Institute (CRI) is pleased to host its second annual Cancer Immunotherapy Month in June, aimed at increasing awareness of cancer immunotherapy, also known as immuno-oncology, a class of cancer treatment that mobilizes the immune system to fight the disease. Immunotherapy was named Science magazine's 2013 Breakthrough of the Year, and is anticipated once...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related